Latest News of DRUG
Venom Helped Create Weight-Loss Drugs. What Else Could It Do For Us?
By The New York Times |
16 hours ago
Dr. Jean-Pierre Raufman's unexpected discovery of a potential diabetes therapy from Gila monster venom illustrates how serendipity can lead to groundbreaking medical advancements. Venom research offer...
John Mulaney reveals Olivia Munn began randomly drug testing him during her pregnancy
By USA Today |
1 day ago
John Mulaney and Olivia Munn discuss their journey to a happy family life in a GQ interview. Munn staged an intervention for Mulaney during her pregnancy, leading to his successful recovery from addic...
Amgen stock falls as analysts mull over weight loss drug's bone density data
By CNBC |
1 day ago
Amgen's MariTide injection for weight loss caused a 7% stock drop due to concerns over bone density loss. Analysts debated its safety risk, with some calling it an overreaction and others urging more ...
-
2 drug companies to pay $260M after jury finds them liable for city's opioid crisis
By CBS News | 1 day agoTwo drug companies in Baltimore were found liable for the city's opioid crisis, leading to a $266 million payment split between McKesson and AmerisourceBergen. The trial revealed allegations of priori...
-
John Mulaney Says Olivia Munn Staged Mini-Intervention, Began Randomly Drug-Testing Him When She Was 6 Months Pregnant
By PEOPLE.com | 1 day agoEscher Walcott, a Writer/Reporter at PEOPLE, covers entertainment, style, and human interest stories. John Mulaney opens up about his addiction recovery journey, with the support of his wife Olivia Mu...
-
Exclusive-Pfizer explores sale of hospital drugs unit, sources say
By Yahoo! Finance | 1 day agoPfizer is considering selling its hospital drugs unit to divest non-core assets, following pressure from activist investor Starboard Value. The unit, Pfizer Hospital, focuses on antibiotics and steril...
-
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials
By Yahoo! Finance | 1 day agoAbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment....
-
'Larger than Life' boy band doc top bombshells: Prison performances, drugs, stolen money and purity rings
By Fox News | 1 day agoThe Paramount+ documentary "Larger Than Life: Reign of the Boybands" delves into the highs and lows of famous boy bands like New Kids on the Block, *NSYNC, and Backstreet Boys....
-
Is Ozempic the modern wonder drug? All the conditions the weight loss...
By New York Post | 1 day agoOzempic, a diabetes medication, is being explored for treating various conditions beyond diabetes and obesity. GLP-1 drugs like Ozempic show promise in reducing inflammation and aiding in conditions l...
-
ViiV Healthcare shares results from trial of Dovato and three-drug therapy for HIV
By Yahoo! Finance | 1 day agoViiV Healthcare presented results from the DOLCE trial, showing Dovato's efficacy in treating advanced HIV comparable to a three-drug therapy. The study demonstrated similar viral suppression rates an...
-
Novo Nordisk Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
By MarketWatch | 2 days agoNovo Nordisk is developing a promising obesity drug that may outperform existing options. Results of a clinical trial are anticipated in December, potentially boosting Novo's shares....
-
Al Roker Says He's 'Not Gonna Judge Anybody' Taking Weight Loss Drugs: 'It's Unlike Any Other Addiction'
By PEOPLE.com | 2 days agoAl Roker, a TV personality, shares his weight loss journey and supports different paths to health. He emphasizes understanding and non-judgment towards those using weight loss medications. Roker advoc...
-
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints
By MarketWatch | 2 days agoBristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%....
-
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
By MarketWatch | 2 days agoAbbVie's stock dropped significantly as their schizophrenia drug, emraclidine, failed to show significant improvement in two Phase 2 trials. The drug did not meet the primary endpoint of demonstrating...
-
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
By Yahoo! Finance | 2 days agoAbbVie Inc. faces a setback as its drug for schizophrenia failed in trials, causing shares to drop significantly. This news benefits Bristol Myers Squibb Co., which recently gained approval for a new ...